Health
Combination immunotherapy benefits subset of patients with advanced prostate cancer. – Brinkwire
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), an “immune-cold” cancer that does not typically respond well to immunotherapy.
In a cohort of patients without previous chemotherapy treatment, the overall response rate (ORR) was 25% and median ove…
-
General16 hours agoThailand punches above its weight in film creativity and cross-border appeal. Here’s why
-
Noosa News17 hours agoRaising your voice | Noosa Today
-
Noosa News8 hours agoNRL live updates: Newcastle Knights vs Melbourne Storm, St George Illawarra Dragons vs Sydney Roosters, North Queensland Cowboys vs Canterbury Bulldogs
-
Noosa News14 hours agoMitch Power Quick Shear event gets men talking about mental health